Evidence has suggested that IL‐18 promotes proliferation and metastasis of pancreatic cancer cell lines through the NF‐κB signalling pathway; however, when co‐administered with BAY11‐7082, an NF‐κB inhibitor, IL‐18 improved survival in a murine model of PDAC.20 Here, NFKB1 is linked to pancreatic neoplasm.